CTI BioPharma Corp. (CTIC)
CTI BioPharma Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Seattle, WA, US. The stock last traded at $9.10, up 0.06% on the session, giving a market capitalisation of $1.20B. On trailing twelve-month figures it carries a trailing P/E of -11.51, a net margin of -168.8%. Its beta of 0.83 implies it has historically moved less than the broad market.
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
CTI BioPharma Corp. is most often compared with the following Healthcare names: